Purpose: Despite improved clinical outcomes for the majority of patients, nearly 30% of patients with rheumatoid arthritis (RA) who initiate tumor necrosis factor antagonist (anti-TNF) biologic agents fail to respond to their first-line anti-TNF and switch to another anti-TNF or a non-TNF biologic. How this change affects health care costs and resource utilization is unknown. We therefore compared RA patients taking first-line antiTNFs who switched to a second anti-TNF versus those patients who switched to an alternate biologic.
Methods: Health care claims data were obtained from a large US database for eligible adults with confirmed RA diagnoses who initiated anti-TNF treatment and switched to another biologic. Health care costs and utilization during the first 12 months' postswitch were compared. Generalized linear models were used to adjust for differences in demographic and clinical characteristics before switching.
Findings:
Patients who switched to a second anti-TNF rather than a non-TNF biologic were generally younger (53.0 vs. 55.3 years; P o 0.0001) and less likely to be female (79.7% vs. 82.7%; P ¼ 0.0490). Of the 3497 eligible patients who switched from first-line anti-TNFs, 2563 (73.3%) switched to another anti-TNF and 934 (26.7%) switched to a non-TNF. Adalimumab was the most frequently prescribed (43.4%) second-line anti-TNF, and abatacept was the most common non-anti-TNF (71.4%). Patients who switched to a second anti-TNF remained on their first medication for a significantly shorter period (342.5 vs 420.6 days; P o 0.0001) and had lower comorbidity indices and higher disease severity at baseline than those who switched to a non-anti-TNF. After adjusting for baseline differences, patients who switched to second anti-TNFs versus a non-TNF incurred
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disorder causing joint pain and swelling that progresses to joint tissue and bone destruction. 1 The prevalence of RA is estimated at 1.5 million adults in the United States, which has significant economic implications for both individual patients and society. 2 Each year, RA is responsible for 4250,000 hospitalizations and 49 million physician visits in addition to a decrease in life expectancy of 3 to 10 years. 3, 4 Moreover, excess health care costs for patients with RA in the United States have been estimated at $8.4 billion annually, with an additional $10.9 billion lost due to functional and work limitations (prices in 2005 US dollars). 5 Appropriate pharmacy and medical policies for the management of patients with RA based on clinical and economic data are imperative for improving patient outcomes while controlling health care costs at the population level.
In the past decade, tumor necrosis factor antagonist (anti-TNF) use has changed the treatment paradigm, with improved clinical outcomes for RA patients with moderate to severe disease. 6 Anti-TNF combination therapy with methotrexate (MTX) has been shown to be a cost benefit, compared with conventional diseasemodifying antirheumatic drug therapy, and has demonstrated slowing of radiographic progression. 7 However, nearly 30% of patients with RA fail to respond to their first anti-TNF agent or experience adverse events by 2 years of therapy. 8 Subsequent therapeutic options include switching to another anti-TNF or to a non-TNF biologic agent. The availability of multiple biologic agents has engendered the question of whether switching to a different TNF inhibitor versus switching to a non-TNF biologic will lead to different clinical and economic outcomes after failure to respond to the initial anti-TNF. Several managed-care medical policies require treatment with at least 2 TNF inhibitors before switching to an alternate biologic agent. 9 These policies are based on the results of controlled clinical trials and observational studies that have shown benefit for a number of patients who failed to respond to initial anti-TNF therapy and who switched to another TNF inhibitor. [10] [11] [12] [13] In these studies, patients were more likely to respond to a subsequent anti-TNF agent if previous anti-TNF treatment was discontinued because of adverse reactions. 14, 15 Although there are controlled clinical trials evaluating the efficacy and safety of non-TNF biologic agents in patients who have failed to respond to anti-TNF therapy, there are few head-to-head studies that directly compare switching to a second anti-TNF versus switching to a non-TNF biologic agent. [16] [17] [18] A recent study of observational data from the Consortium of Rheumatology Researchers of North America, Inc. (CORRONA) RA registry, which enrolls RA patients from private and academic institutions across the United States, found that clinical outcomes after a switch from one TNF inhibitor to a second TNF inhibitor were similar to those observed when switching to abatacept (ABA). 19 Although this study evaluated clinical outcomes in an observational setting, an economic evaluation was not conducted. The latter is an important issue because the cost-effectiveness associated with switching to a secondline biologic agent is poorly defined, although studies have shown that, after a switch in treatment, patients incur higher costs compared with those who do not switch. 20, 21 It is possible that both clinical and economic evaluation of biologic switching may guide policy development to ensure this disabling disease is controlled at the population level while managing overall health care costs.
The objective of the present study, therefore, was to evaluate the impact on health care costs and resource utilization of switching from a first-line anti-TNF therapy to a second biologic agent. We also examined whether there was a differential impact on cost and resource utilization associated with switching to a second anti-TNF agent compared with switching to a non-TNF antagonist.
PATIENTS AND METHODS Data Source
The Truven Health MarketScan Commercial Claims and Encounters Database and the Medicare Supplemental and Coordination of Benefits database from January 2004 through December 2010 were used in this retrospective study. These databases capture the full continuum of care in all settings, including physician office visits, inpatient stay, emergency department (ED) visits, and retail, mail order, and specialty pharmacy claims, as well as patient demographic and enrollment information. Patients were considered to have switched therapy if they had been prescribed another anti-TNF or non-TNF biologic agent without successive claims of the initial biologic agent. A minimum 12-month biologicfree period was required before the first anti-TNF agent. In addition, all patients in this study were required to have at least 12 months of continuous medical and pharmacy benefits before the first anti-TNF claim date and for 12 months after the switch date. The switch date was designated as the index date. All baseline variables were calculated for the 12 months before the index date (baseline period), and outcome variables were calculated for the 12 months after the index date (follow-up period).
Study Sample

Informed Consent
No patient identity or medical records were disclosed for the purposes of this study except in compliance with applicable law. Because the core study proposed herein does not involve the collection, use, or transmittal of individual identifiable data, patient approval/consent to conduct this study was not required.
Cohort Assignments
To compare patients who switched to another anti-TNF biologic versus those who switched to a non-anti-TNF biologic, 2 cohorts were created. The anti-TNF biologic switcher cohort consisted of patients who initiated ETN, ADA, or IFX and later switched to ETN, ADA, IFX, golimumab, or certolizumab. The non-TNF biologic switcher cohort was composed of patients who initiated ETN, ADA, or IFX and later switched to ABA, anakinra, or rituximab. 28 Higher SIFRA scores indicate increased disease severity, and the Elixhauser index has shown evidence of being a significant determinant of total and RA-related health care costs for patients with RA.
Baseline Covariates
26
Other baseline measures included RA-related treatments such as NSAIDs, corticosteroids, xenobiotics, MTX, and cytotoxic therapy. Baseline health care costs (including total all-cause pharmacy, knee and hip replacement surgery, laboratory tests, hospitalization, and ED and physician office visit costs) were also measured. Physician prescribing patterns were calculated as the percentage of times the first-line anti-TNF biologic agent was prescribed. Days from the first anti-TNF claim to the index date were calculated to determine the time to therapy switch.
Outcome Variables
Total all-cause health care costs, in addition to those associated with pharmacy, knee and hip replacement surgery, laboratory tests, hospitalization, and ED and physician office visits, were calculated for the 12-month follow-up period. Total RA-related health care costs were calculated by using medical claims with an RA diagnosis claim in any position. RA-related pharmacy costs were calculated for anti-TNF, NSAIDs, corticosteroid, xenobiotic, cytotoxic therapy, and MTX pharmacy claims. Health care costs were calculated on the basis of the amount paid by the health care plan for relevant claims and the net cost of any patient contribution (eg, copayment). Costs are expressed in 2012 US dollars and were adjusted by using the medical care component of the US Consumer Price Index. For health care utilization estimates, the number and binary indicator of hospitalizations, ED visits, and physician office visits were calculated for the follow-up period. The follow-up period SIFRA score, which was validated by using a large claims database, 27 was used to measure disease severity.
Statistical Analysis
Descriptive and bivariate analyses were performed for the anti-TNF and non-TNF switcher cohorts for baseline and outcome variables. Percentages and SDs were calculated for dichotomous variables, and means and SDs were calculated for continuous variables.
Clinical Therapeutics
P values were generated by using the χ 2 test and Student t test for dichotomous and continuous variables, respectively.
Multivariate analysis was performed by using a generalized linear model, in which log link and gamma distributions were used for cost outcomes, negative binomial distribution was used for count variables (eg, number of health care utilization visits), and logistic distribution was used for binary outcomes (eg, having at least 1 visit). Variables included in the model were age, sex, geographic region, health care plan type, index year, index copay, baseline CCI score, Chronic Disease Score, Elixhauser index score, other individual comorbidities, physician prescribing patterns, baseline RA therapies, and health care utilizations and costs. Descriptive and multivariate results were compared between the anti-TNF biologic switcher cohort and the non-TNF biologic switcher cohort.
RESULTS
A total of 234,483 patients were identified for inclusion in the study during the identification period 
Baseline Demographic and Clinical Characteristics
Patients who switched to a second anti-TNF rather than a non-TNF biologic were generally younger (53.0 vs 55.3 years; P o 0.0001) and less likely to be female (79.7% vs 82.7%; P ¼ 0.0490) ( Table I) . The time to switch from one anti-TNF to another was shorter compared with switching to a non-TNF biologic (342.5 vs 420.6 days; P o 0.0001). In addition, patients who switched to a second anti-TNF were more likely to have an initial prescription for ETN (49.0% vs 30.3%; P o 0.0001) or ADA (38.1% vs 30.9%; P ¼ 0.0001) than IFX (12.9% vs 38.8%; P o 0.0001), compared with those who switched to a non-TNF biologic (Table II) .
During the baseline period, patients who switched to a second anti-TNF compared with a non-TNF biologic had higher SIFRA scores (4. Table II) . In terms of RA-related medication and therapies, anti-TNF switchers were less likely to be prescribed corticosteroids (73.5% vs 76.9%; P ¼ 0.0436) but more likely to be prescribed MTX (64.1% vs 57.4%; P ¼ 0.0003) compared with non-TNF switchers.
The initial route of administration also played a significant role in the switching methods. Those who were initially taking a subcutaneous anti-TNF biologic (eg, ETN, ADA) were more likely to receive a subsequent anti-TNF agent. In contrast, those who were initially treated with an infused anti-TNF (IFX) were more likely to be treated with a non-TNF versus a second anti-TNF biologic (25.4% vs 23.7%; P ¼ 0.004).
Baseline Health Care Costs
During the 12 months before switching therapy, anti-TNF biologic switchers incurred lower total health care costs than non-TNF biologic switchers ($23,088.4 vs $31,108.0; P o 0.0001). Of the cost categories evaluated, hospitalization ($2788.4 vs $6229.1; P ¼ 0.0003), laboratory tests ($543.1 vs $656.6; P ¼ 0.0050), pharmacy ($12,652.5 vs $13,747.7; P ¼ 0.0036), and physician office visits ($1480.9 vs $1798.0; P o 0.0001) costs were lower in the anti-TNF group (Table III) .
Risk-Adjusted Outcomes
After controlling for baseline demographic and clinical differences by using a generalized linear model, anti-TNF biologic switchers incurred significantly lower all-cause costs ($34,894. Total pharmacy (including non-TNF, anti-TNF, and all outpatient pharmacy costs), knee and hip replacement surgery, hospitalization, laboratory tests, and ED visit costs were similar for anti-TNF biologic switchers and non-TNF biologic switchers. However, anti-TNF biologic switchers had fewer physician office visits (15.0 vs 19.3; P o 0.0010), which translated into lower associated costs ($1535.1 vs $1993.6; P o 0.0010) ( Table IV) . In addition, anti-TNF biologic switchers incurred significantly lower RA-related costs compared with non-TNF biologic switchers during the follow-up period.
DISCUSSION
Several studies have found that patients with RA who switch to a second biologic agent of any mechanism incur higher medical costs both before and after the switch compared with patients who continue treatment with their initial biologic agent. 20, 21, 29 One large retrospective claims analysis reported that baseline monthly health care costs were 27% higher for patients who switched first-line biologic therapy compared with nonswitchers. 21 This study also found that postswitching costs were increased by 35% for firstline biologic switchers versus nonswitchers, after controlling for potential confounders. Together, these data indicate that switching biologic therapy is associated with increased costs. The present study found that numeric costs were higher in the 12 months after a switch from a TNF inhibitor to a non-TNF compared with a second anti-TNF. Although specific reasons for the switch were not evaluable in this study, switching patterns seemed to be based on the initial prescription. Of patients who were initiated on a self-injectable biologic (ADA or ETN), approximately three quarters were switched to another subcutaneously administered anti-TNF. However, 50% of those initiated on IFX were switched to an agent with an alternate mechanism of action. The difference in costs could not be explained by differences in patient characteristics at the time of the switch. Those switched to a non-TNF were more likely to be female, to be older, and to have more comorbidities than those who did not switch. Interestingly, the degree of RA disease severity was lower in those who switched to a non-TNF. The increased cost of switching to a non-TNF biologic remained after controlling for these differences. At the time of our analysis, ABA was available as an intravenous infusion administered monthly. Because 70% of non-TNF switches were to ABA, it is possible that the increased office visit costs and number of visits in the non-TNF group may be related to the increased frequency of infusions for ABA compared with IFX (monthly vs every 8 weeks). As of July 2011, ABA became available for subcutaneous administration 30 ; the 2 administration methods may influence future studies evaluating switching from an anti-TNF biologic to a non-TNF biologic.
Few other studies have directly compared anti-TNF versus non-TNF biologic agents after failure of an initial biologic. Available data demonstrate that the reason for switching biologic agents is important in predicting the chance of treatment success for the second-line agent. [31] [32] [33] [34] Efficacy of TNF sequencing is highest among patients who discontinue their anti- TNF agent (owing to tolerability or waning efficacy) and lower among patients who switch primarily due to an inadequate response to Z1 agent. 8, 13, 18, [35] [36] [37] [38] A meta-analysis of 31 studies (incorporating 5306 patients) was conducted; the majority (77%) of the studies were prospective cohort studies and 1 was a randomized controlled trial. These studies demonstrated that efficacy after switching between TNF inhibitors is lowest after a primary inadequate response and an inadequate response to 42 agents. 39 Evidence from randomized controlled trials also showed that anti-TNF nonresponders can attain an efficacious response by switching to a second anti-TNF agent. 11, 16, 17, [40] [41] [42] [43] [44] Using data from the COR-RONA registry, Harrold et al 19 directly evaluated the impact on clinical outcomes of switching to a second anti-TNF compared with switching to ABA. After adjusting for a number of previous anti-TNF therapies, baseline disease activity, RA disease severity, and concomitant medications, clinical outcomes were 
Costs (2012 US $)
Anti-TNF Non-TNF Figure 3 . Risk-adjusted all-cause and rheumatoid arthritis (RA)-related health care costs of tumor necrosis factor antagonist (anti-TNF) versus non-TNF biologic switcher cohorts during the follow-up period. *P ¼ 0.0010. similar. Schabert et al 45 used a health insurance claims database and a published claims-based algorithm as a proxy to estimate treatment effectiveness for low disease activity or remission among RA patients switching from an anti-TNF to a subsequent anti-TNF or ABA. Although ABA was slightly more effective as a second-line biologic than a second anti-TNF (25% for ABA, 22% for ETN, 21% for ADA, and 11% for INF), the cost per responder was lower for both ETN and ADA compared with ABA ($66,449, $71,877, and $87,563, respectively). These results by Schabert et al may explain the current finding of lower all-cause and RA-related health care costs in the 12 months after a switch to a second TNF inhibitor compared with a non-TNF biologic.
One strength of the present study is that we controlled for baseline differences in disease severity.
SIFRA is a more robust measurement of RA severity than other comorbidity indices, such as the CCI, the Elixhauser index, or the Chronic Disease Score. 27 The inclusion of SIFRA improved the strength of our study and controlled for the important observed bias for which previous research had not controlled. 26 Second, the present study evaluated the route of administration for the initial anti-TNF and how this affected what agent patients received as second-line therapy. The administration route was found to be strongly related to the anti-TNF or non-TNF biologic agents to which patients were switched. In addition, this retrospective study used a large commercial US claims database and a 7-year observation period, which made it more nationally representative than some previous studies. [46] [47] [48] [49] [50] There are some limitations to this study, however. First, because of the retrospective study design, it is difficult to be certain of causal relationships, and only the association between the noted variables and outcomes could be calculated. Second, due to the time frame in which the study was conducted, all biologic agents that are currently available for the treatment of RA were not included in the analysis. There are additional non-TNF biologic agents available for subcutaneous administration. Third, due to the nature of the claims database, the presence of a claim for a filled prescription does not indicate whether the medication was actually used as prescribed. Fourth, unmeasured confounding variables may have affected results of the multivariate analysis. For example, clinical data are not provided in the databases; therefore, the reason for treatment failure is unknown. Patients may switch from an initial anti-TNF biologic agent because of a lack of efficacy, adverse event/ toxicity, or nonmedical reasons such as cost/insurance, but adjusting for these differences was not possible in this study. Another important variable to note is the different approval dates of the biologic agents, which may influence prescribing patterns.
CONCLUSIONS
The results from the present study indicate that in the real world, switching to a second anti-TNF was associated with reduced cost compared with switching to a non-TNF biologic. Because head-to-head data directly comparing the clinical efficacy of switching to a second-line biologic do not consistently support 1 agent over another, using the strategy that results in the lowest overall cost to the system maybe a prudent approach in mitigating health care costs. Further studies are warranted to evaluate biologic switching and should include reasons for the switch, clinical outcomes, and cost. This information can assist policy makers in developing appropriate clinical pathways that will ensure appropriate disease control while managing total health care costs.
